ClinicalTrials.gg
TerminatedNCT00809536Updated Feb 17, 2010

Investigation Of How PD 0332334 And Metformin Are Eliminated From The Body When They Are Administered At The Same Time

A Phase 1 interventional study of Metformin and Metformin in Generalized Anxiety Disorder, sponsored by Pfizer. Terminated at 1 site in Singapore. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-02-17.

Sponsored by Pfizer · Phase 1 and Interventional

Why this study was terminated
Please Detailed Description for termination reason.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
21 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 11 studies testing imagabalin in Generalized Anxiety Disorder — none open to participants now, none under way, none of them phase 3. imagabalin · Generalized Anxiety Disorder.

Enrollment
7th of 11
24 · median 222
Started
2009
with 3 others
Phase 1
4 of 11
none open now
Registered
9th of 11
by date
Lead sponsor
11 of 11
Pfizer

Among the 11 studies testing imagabalin in Generalized Anxiety Disorder, this one is the 7th largest by enrollment, is one of 4 that started in 2009, is one of 4 in phase 1, and was the 9th registered.

Generalized Anxiety Disorder

518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.

Browse Generalized Anxiety Disorder studies →

Open to participants now

None of the 11 studies testing imagabalin in Generalized Anxiety Disorder is open now. The open studies under Generalized Anxiety Disorder, anywhere →

About imagabalin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 87 Generalized Anxiety Disorder studies recruiting now, 32 (37%) set no upper age limit and 53 (61%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.

This study: 21 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing imagabalin in Generalized Anxiety Disorder as a file.
02

Study summary

  1. To estimate the effects of multiple doses of PD 0332334 on the elimination of a single dose of metformin from the body
  2. To estimate the effects of multiple doses of metformin on the elimination of a single dose of PD 0332334 from the body
  3. To evaluate the safety and tolerability when PD 0332334 and metformin are administered at the same time.
Read the detailed description

Detailed Description:

Additional Study Purpose Details: To assess the pharmacokinetics of metformin and PD 0332334 with concurrent administration.

On February 18th 2009, a decision to terminate further development for PD 0332334 was communicated to investigators in this study. The decision to terminate this study was not based on any safety concerns.

03

Conditions studied

  • Generalized Anxiety Disorder

Keywords

  • metformin, PD 0332334, organic cation transporter, OCT2, pharmacokinetics
04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Nonsmokers
  • Male or female adults

Exclusion criteria

Exclusion Criteria:

  • Current or history of significant medical illness
  • Smokers
  • Illicit drug use
05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Other
    Cohort 1

    This is an open-label, randomized, two period cross-over which will be conducted in 12 healthy adults

    Drug: Metformin

  • Other
    Cohort 2

    This is an open-label, randomized, two period cross-over which will be conducted in 12 healthy adults

    Drug: PD 0332334

Interventions

  • 225 mg q12, oral PD 0332334 immediate release formulation on Days 1 through 5; Single, oral, 500 mg dose of metformin immediate release

    Also known as: imagabalin

  • Single, oral, 500 mg of metformin immediate release

  • 500 mg q12, oral metformin immediate release administered on Days 1 through Day 6 Single, oral, 300 mg dose of PD 0332334 immediate release formulation administered on Day 3

  • Single, oral, 300 mg dose of PD 0332334 immediate release formulation

06

What researchers measure

Primary outcomes

  1. Metformin and PD 0332334 area under the curve (AUC) from time 0 to infinity (AUCinf)

    Time frame: Days 1 through 7

  2. Metformin and PD 0332334 AUC from 0 to last quantifiable concentration (AUClast)

    Time frame: Days 1 through 7

  3. Metformin and PD 0332334 half-life (t1/2)

    Time frame: Days 1 through 7

  4. Metformin and PD 0332334 maximum plasma concentration

    Time frame: Days 1 through 7

Secondary outcomes

  1. Clinical safety laboratories

    Time frame: Days 1 through 7

  2. Incidence, duration and severity of adverse events when study medications administered alone and concurrently

    Time frame: Days 1 through 7

  3. Discontinuation due to adverse events when study medications administered alone and concurrently

    Time frame: Days 1 through 7

  4. 12-lead ECGs

    Time frame: Days 1 through 7

  5. Vital signs

    Time frame: Days 1 through 7

07

Study locations

1 site
  • Pfizer Investigational Site
    Singapore, 188770, Singapore
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2008
First posted
Dec 17, 2008
Start
Jan 2009
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Last update
Feb 17, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00809536
Lead sponsor
Pfizer
First posted
Dec 17, 2008
Start date
Jan 2009
Primary completion
Feb 2009
Completion
Feb 2009
Last update
Feb 17, 2010

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Metformin · Imagabalin

Start the discussion